AI has been widely discussed from the perspective of technology, and tech funds are the only ones that have seen huge inflows. In contrast, biotech funds have been crushed, not pricing in how transformative the endless AI aplications will be for this sector. How will the biotechnology industry and healthcare be impacted and become one of the biggest winners? How this sector's recent performance could represent a buy opportunity?
Combining advances in biotechnology and AI creates unprecedented solutions that contribute to the fulfillment of global sustainability development goals. Among all of these advantages are:
-Advancing the speed and quality of already established biological processes, like: drug manufacturing, chemical analyses and DNA/RNA sequencing.
-Data access and automation to improve the efficiency and accuracy in research and development.
-Digital transformation to enable the discovery and development of entirely new and disruptive drugs, products and services.
-Resonating impact across all areas of biotechnology, including: agricultural, forest, medical, animal, military and bioinformatics.
Given the fact biotech funds have been down for a while ($XBI -18% YTD & -20% 3-month, $IBB -8% YTD & -6% 3-month, $IBBQ -8% YTD & -4% 3-month), and don't account for how transformative AI will be for this sector, is this the time to buy?
Leave a Reply